chimeric antigen receptor t cells
Dangdai Invests Over US$43 Million In CBMG
Dangdai's investment in CMBG will help further long-term clinical trials for stem cell therapies and chimeric antigen receptor T-cell trials for selected cancers.
The Unassuming Revolutionary
Asian Scientist Magazine catches up with the inventor of optogenetics and CRISPR gene editing, Zhang Feng.
Yao Yihong Appointed CBMG CSO
Dr. Yao Yihong has been appointed as CBMG's chief scientific officer to lead research programs in immuno-oncology and autoimmune/inflammatory diseases.
CBMG Expands Beijing GMP Facility
CBMG will open a third GMP facility in Beijing to develop their immunotherapy platform, CAR-T.
WuXi To Build Third Cell Therapy Facility
The company's third cell therapy manufacturing facility will focus on chimeric antigen receptor T cells for cancer immunotherapy.
CBMG Acquires Novel T-Cell Therapy Technology
The CAR-T cell therapy developed at the Chinese People's Liberation Army General Hospital uses cancer patient's own immune cells to attack tumors.
